TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse ...

TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split-adjusted ...

TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash ...

As previously announced, the 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stock into one new share of common stock. No fractional shares ...

TransCode Therapeutics, Inc. BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Read Also: ‘Pharma Bro’ Martin Shkreli Tells Investors To ‘Short SAVA,’ Stock Falls Over 80% After Phase 3 Update According to data from Benzinga Pro, RNAZ has a 52-week high of $18.48 and ...

TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8M before ...

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a company focused on cancer treatment using RNA therapeutics, said on Monday that its Board has approved a 1-for-33 reverse stock split. This move ...